Could a Triple-Drug cocktail tame tough breast cancer?
Disease control
Completed
This study tested whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy (paclitaxel) and a targeted drug (bevacizumab) helps people with a common type of advanced breast cancer (HR-positive, HER2-negative). The trial enrolled 281 participants whose cancer h…
Phase: PHASE3 • Sponsor: Japanese Foundation for Cancer Research • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC